Chi­na's KBP Bio is com­ing to Amer­i­ca, with $76M A round and GSK vet tak­ing the helm in Philly

Over the past 5 years KBP Bio­sciences has been steadi­ly grow­ing up its pipeline of new drugs from its base in Chi­na. But this morn­ing the biotech com­pa­ny is un­veil­ing a dra­mat­ic change of scene, with plans to set up a glob­al head­quar­ters in Philadel­phia while tak­ing the wraps off a $76 mil­lion ven­ture round that will give its new Amer­i­can CEO the cash to make a splash at the FDA.

The new CEO is Bri­an McVeigh, a 25-year vet­er­an of Glax­o­SmithK­line, where un­til very re­cent­ly he head­ed up the glob­al busi­ness de­vel­op­ment team in­side the phar­ma gi­ant’s ex­ten­sive Philly hub. McVeigh tells me he plans to put that BD ex­pe­ri­ence to work for KBP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER